(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



. | 1865 | 1865 | 1865 | 1865 | 1865 | 1865 | 1865 | 1865 | 1865 | 1865 | 1865 | 1865 | 1865 | 1865 | 1865 | 1

(43) International Publication Date 23 September 2004 (23.09.2004)

PCT

(10) International Publication Number WO 2004/080999 A1

- (51) International Patent Classification⁷: C07D 401/12, 405/14, 401/14, 409/14, 409/12, 413/12, 231/14, A61K 31/4155, A61P 29/00
- (21) International Application Number:

PCT/GB2004/001054

- (22) International Filing Date: 12 March 2004 (12.03.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0300705-1 60/482,563 14 March 2003 (14.03.2003) SE 26 June 2003 (26.06.2003) US

- (71) Applicant (for all designated States except US, UZ): BI-OLIPOX AB [SE/SE]; P.O. Box 6280, S-102 34 Stockholm (SE).
- (71) Applicant (for UZ only): MCNEENEY, Stephen, Phillip [GB/GB]; Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HALLBERG, Anders [SE/SE]; Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, P.O. Box 574, S-751 23 Uppsala (SE). SCHAAL, Wesley [US/SE]; Biolipox AB, P.O. Box 6280, S-102 34 Stockholm (SE). LARHED, Mats [SE/SE]; Department of Medicinal Chemistry, Biomedical University, P.O. Box 574, S-751 23 Uppsala (SE). OLOFSSON, Kristofer [SE/SE]; Biolipox

AB, P.O. Box 6280, S-102 34 Stockholm (SE). PEL-CMAN, Benjamin [SE/SE]; Biolipox AB, P.O. Box 6280, S-102 34 Stockholm (SE). SANIN, Andrei [RU/SE]; Biolipox AB, P.O. Box 6280, S-102 34 Stockholm (SE).

- (74) Agent: MCNEENEY, Stephen; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION

$$\begin{array}{c}
O \\
N \\
N \\
Y \\
X
\end{array}$$

$$\begin{array}{c}
R^1 \\
R^2 \\
(I)
\end{array}$$

(57) Abstract: There is provided a compound of formula (I), wherein R¹, R², R³, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.